The Cardiovascular Diseases segment accounted for approximately 13.7% of market revenue in 2025 and is growing at a CAGR of 18.1% , driven by the expanding cardiovascular label and ongoing phase 3 programs evaluating semaglutide in heart failure with preserved ejection fraction (STEP-HFpEF), obese patients undergoing cardiac rehabilitation, and other cardiometabolic settings
There isnt hard science on the best time, but its something you can experiment with (again, with doctors input) if side effects are impacting your schedule
No outside funding was disclosed
Track your response for two full weeks at the new dose before evaluating whether to increase again
We are currently unable to fill these medications in our pharmacy, although there are other pharmacies in the Baton Rouge area that are able to fill them
It's really great for fat burning to some smaller extent, and it's good for just longevity and all that other stuff